Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments

Medicus Pharma Ltd.

Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.
Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.
Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.
Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).
Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.